Published: Jun, 2018

The global orphan drugs market is expected to witness the emergence of several new players over the coming years. The tremendous development of with the field of drug development has been the key reason behind the emergence of these new players. Currently, the market for orphan drugs consists of a wide pool of competitive market vendors who have learnt, evolved, and developed as experts of drug manufacturing through years of experience. Furthermore, these leading market players have been focusing on building an agile and nimble framework for the manufacture of orphan drugs. In order to do this, these vendors have recruited skilled researchers, scientists, and professionals who are trained in the domain of drug development. It is anticipated that the strongholds of the leading players in the global market for orphan drugs would pose as a threat to the growth of the smaller players. It is projected that the small- and medium-sized market players would rely on the incentives provided by the government to sustain themselves. The new entrants are expected to start from the basics by producing elementary drugs and then advancing on to producing more complex orphan drugs. The key players in the global market for orphan drugs include Celgene Corporation, Novartis AG, Pfizer Inc., GlaxoSmithKline plc, Alexion Pharmaceuticals Inc., and Johnson & Johnson. These leading market players have attained expertise in the manufacture of orphan drugs and are expected to further elevate their manufacturing gradient.

A report published by Transparency Market Research (TMR) builds a foundation to gauge the success rate of the global market for orphan drugs over the coming years. The report predicts that the global market for orphan drugs would expand at starry CAGR of 12.10% over the period between 2017 and 2025. Furthermore, the global market is expected to accumulate a net value of US$318.5 bn by 2025-end.

orphan drugs market

Rising Incidence of Cancers to Propel Demand

The field of oncology is faced by tremendous pressure to deal with the increasing number of patients diagnosed with cancer each year. Several rare type of cancers have been discovered and diagnosed in recent times, thus, calling for an urgent need to effectuate administration of important drugs. Since orphan drugs are developed specifically for the treatment of a particular disorder or diseases, the demand for these drugs has been escalating in recent times. Furthermore, typical cases of cardiovascular and metabolic disorder also propel demand for orphan drugs. Other types of disorders and diseases that propel market demand are related to hematology, endocrinology, and infectious diseases.

Government Support to Trigger Market Growth

The area of drug discovery and development has been the most key segment of the medical and pharmaceutical industries. Hence, the government has made huge-scale investments towards building a robust framework for drug discovery and development. This has given an impetus to the growth of the global market for orphan drugs in recent times. Furthermore, the return on investment in orphan drugs is projected to substantially higher than that of non-orphan drugs. This has also led to an increased demand within the global market for orphan drugs and has subsisted growth of market players.

The review is based on TMR’s report titled “Orphan Drugs Market (Disease Type - Oncology, Gastrointestinal, Pulmonary, Neurology, Hematology, Cardiovascular, Metabolic disorders, Endocrinology, and Infectious diseases; Product Type - Biologic and Non-biologic; Distribution Channel - Hospital Pharmacies, Specialty Pharmacies, Retail Pharmacies, and others) - Global Industry Analysis, Size, Share, Volume, Growth, Trends, and Forecast 2017 – 2025”

The global orphan drugs market is segmented as follows:

  • Orphan Drugs Market, by Disease Type, Revenue (US$ Bn) 2015-2025
    • Oncology
    • Gastrointestinal
    • Pulmonary
    • Neurology
    • Hematology
    • Cardio-vascular
    • Metabolic disorders
    • Endocrinology
    • Infectious diseases
    • Others
  • Orphan Drugs Market, by Product Type, Revenue (US$ Bn) 2015-2025
    • Biologic
    • Non-biologic
  • Orphan Drugs Market, by Distribution Channel, Revenue (US$ Bn) 2015-2025
    • Hospital Pharmacies
    • Specialty Pharmacies
    • Retail pharmacies
    • Others
  • Orphan Drugs Market Revenue, by Geography (US$ Bn), 2015-2025
    • North America
      • U.S.
      • Canada
    • Europe
      • U.K.
      • Germany
      • Spain
      • France
      • Italy
      • Rest of Europe
    • Rest of the World
      • Japan
      • Australia
      • China
      • Brazil
      • South Korea
      • Others

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through adhoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

Contact Us

Transparency Market Research
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
USA - Canada Toll Free: 866-552-3453